Celltrion’s Kim Emphasizes Innovation As Pipeline Grows

But Company Sees US Biosimilar Interchangeability Designation As ‘Unnecessary’

 
• By David Wallace
  
Generate a summary of this article
Listen to this article
Beta

Celltrion will adopt a “next generation” innovative approach to developing biosimilars as it continues to bolster its pipeline, HoUng Kim, head of Celltrion Healthcare’s medical and marketing division, tells Generics Bulletin in an exclusive interview. But the firm sees the US interchangeability designation as an “unnecessary” regulatory barrier.

Dr. HoUng Kim, Head of Medical and Marketing Division at Celltrion Healthcare
HoUng Kim sets out Celltrion’s strategy • Source: Celltrion

With a series of successful biosimilar launches under its belt, as well as innovative products such as its Remsima SC subcutaneous formulation of infliximab, Celltrion is an established player in the biosimilars arena. And with plans to launch a new biosimilar every year between now and 2030, the firm has no intention of slowing down, HoUng Kim – head of Celltrion Healthcare’s medical and marketing division – tells Generics Bulletin in an exclusive interview.

Asked about the Korean company’s most significant successes so far, Kim immediately pointed to the development of Remsima SC as...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.